What does Inavolisib (Itovebi) do in plain English—and how does it work inside your body?
Inavolisib is an FDA-regulated Kinase Inhibitor (RxNorm RxCUI 2695427). Mechanistically, 12.1 Mechanism of Action Inavolisib is an inhibitor of phosphatidylinositol 3-kinase (PI3K) with inhibitory activity predominantly against PI3Kα. In vitro, inavolisib induced the degradation of mutated PI3K catalytic alpha subunit p110α (encoded by the PIK3CA gene), inhibited phosphorylation of the downstream target AKT, reduced cellular proliferation, and induced apoptosis in PIK3CA -mutated breast cancer cell lines. In vivo, inavolisib reduced tumor growth in PIK3CA -mutated, estrogen receptor-positive, breast cancer xenograft models. [1][2].
When your doctor writes a prescription for Inavolisib (RxNorm RxCUI 2695427, also dispensed under brand names including Itovebi), the goal is to target the root physiological pathway driving your condition rather than just masking surface symptoms [1]. According to the official FDA DailyMed package insert, 12.1 Mechanism of Action Inavolisib is an inhibitor of phosphatidylinositol 3-kinase (PI3K) with inhibitory activity predominantly against PI3Kα. In vitro, inavolisib induced the degradation of mutated PI3K catalytic alpha subunit p110α (encoded by the PIK3CA gene), inhibited phosphorylation of the downstream target AKT, reduced cellular proliferation, and induced apoptosis in PIK3CA -mutated breast cancer cell lines. In vivo, inavolisib reduced tumor growth in PIK3CA -mutated, estrogen receptor-positive, breast cancer xenograft models. [2].
Across real-world patient logs on dotMD (89% positive worth-it rating), patients do best when they understand both what the medication is doing on day 1 and how long it takes to reach steady-state protection [3].
Check the imprint code on your Inavolisib tablet bottle and confirm with your pharmacist that it matches your prescribed strength (3 mg/1 Tablet, Film Coated, 9 mg/1 Tablet, Film Coated).